An assessment of Loctite's choice to release Express Scripts Promoting Prescription Drug Home Delivery B Executive Summary, its brand-new immediate adhesive dispenser has heighted the reality that the dispenser would not be matching the company's present product line. The truth that Loctite is a leader in instant adhesives and runs in a market which has low price sensitivity suggests that using a low priced adhesive under Loctite's name would just be minimizing the business's revenue in the long run. With risks of sales cannibalization and sales of Loctite's luxury dispenser's being threatened by the new possible launch, Loctite does not have a legitimate argument for releasing Express Scripts Promoting Prescription Drug Home Delivery B Executive Summary other than the truth that the prototype of the new development has actually been developed and is ready to be released under the company's name.
A recommended marketing mix in case the company chooses to proceed with the launch suggests the cost to be below $250 with the item being targeted at a specific niche segment such as that of the 'motor vehicle repair work' so that the company does not wind up losing the marketplace share of its high-end models to Express Scripts Promoting Prescription Drug Home Delivery B Executive Summary because of the item's low cost. Circulation through distributors is suggested as per the marketing mix rather than going with the sales group given that the expense of each sales call is $120 which would not be a financially practical move for a low cost item. A marketing campaign can not be removed from the marketing mix given that the initial awareness has to be produced in order to reach out to possible consumers in the targeted section.